| Literature DB >> 35336776 |
Mattia Di Bartolomeo1, Francesco Cavani2, Arrigo Pellacani1, Alexis Grande3, Roberta Salvatori4, Luigi Chiarini4, Riccardo Nocini5, Alexandre Anesi4.
Abstract
Biophysical energies are a versatile tool to stimulate tissues by generating biopotentials. In particular, pulsed electromagnetic field (PEMF) stimulation has intrigued researchers since the 1970s. To date, many investigations have been carried out in vivo, but a gold standard treatment protocol has not yet been defined. The main obstacles are represented by the complex setting of PEMF characteristics, the variety of animal models (including direct and indirect bone damage) and the lack of a complete understanding of the molecular pathways involved. In the present review the main studies about PEMF stimulation in animal models with bone impairment were reviewed. PEMF signal characteristics were investigated, as well as their effect on molecular pathways and osseous morphological features. We believe that this review might be a useful starting point for a prospective study in a clinical setting. Consistent evidence from the literature suggests a potential beneficial role of PEMF in clinical practice. Nevertheless, the wide variability of selected parameters (frequency, duration, and amplitude) and the heterogeneity of applied protocols make it difficult to draw certain conclusions about PEMF effectiveness in clinical implementation to promote bone healing. Deepening the knowledge regarding the most consistent results reported in literature to date, we believe that this review may be a useful starting point to propose standardized experimental guidelines. This might provide a solid base for further controlled trials, to investigate PEMF efficacy in bone damage conditions during routine clinical practice.Entities:
Keywords: PEMF; bone; damage; electromagnetic; field; healing; pulsed; regeneration; stimulation
Year: 2022 PMID: 35336776 PMCID: PMC8945722 DOI: 10.3390/biology11030402
Source DB: PubMed Journal: Biology (Basel) ISSN: 2079-7737
Figure 1Example of the electric signal generated by a stimulator. a = positive amplitude; b = positive width; c = negative amplitude; d = negative width.
Main features studied after PEMF stimulations.
| Study Object | Abbreviation Used | Clinical Meaning |
|---|---|---|
| Soluble adenylyl cyclase (sAC), cyclic adenosine monophosphate (cAMP), protein kinase A (PKA), and cAMP response element-binding protein (CREB) signaling pathways | sAC/cAMP/PKA/CREB pathway | Pathway promotes bone formation |
| Wingless-related integration site pathway | Wnt pathway | Pathway promotes bone formation |
| LDL receptor related protein 5 | LRP5 | Enhances Wnt pathway activation |
| Dickkopf1 | DKK1 | Antagonize Wnt pathway activation |
| Sclerostin | Sost | |
| Alkaline phosphatase | ALP | Indirect evaluation of osteoblastic |
| Collagen type I alpha 1 chain | Col1a1 | |
| Osteocalcin | OCN | |
| Procollagen type 1 n-terminal propeptide | P1NP | Indirect evaluation of osteoclastic |
| Cathepsin K | CTSK | |
| Matrix metalloproteinase 9 | MMP9 | |
| Tartrate resistant acic phosphatase | TRAP | |
| CCAAT/enhancer-binding protein alpha | C/EBP-alpha | |
| Peroxisome proliferator-activated receptor gamma | PPAR-gamma | |
| Receptor activator of nuclear factor kappa-Β | RANK | |
| Receptor activator of nuclear factor kappa-Β ligand | RANKL | |
| TNF Receptor Associated Factor 6 | TRAF-6 | Antagonize osteoclastic differentiation and activity |
| Osteoprotegerin | OPG | |
| Bone morphogenetic protein-2 | BMP-2 | Enhance osteoblastic differentiation |
| Fibroblast growth factor | FGF | |
| recombinant human Bone Morphogenetic Protein-2 | rhBMP-2 | |
| Runt-related transcription factor 2 | Runx2 | |
| Transforming Growth Factor Beta 1 | TGF-beta 1 | |
| Placental Growth Factor | PlGF | Play a major role in angiogenesis and vasculogenesis, which are key to |
| Vascular endothelial growth factor | VEGF | |
| Angiopoietin-2 | Ang | |
| Brain-derived neurotrophic factor | BDNF | |
| Tunica interna endothelial cell kinase-2 | Tie-2 | |
| Bone Surface/Bone Volume | BS/BV | Morphometric parameters linked to bone |
| Bone Mineral Density | BMD | |
| Bone Volume | BV | |
| Bone Volume/Total Volume | BV/TV | |
| Connectivity density | Conn.D | |
| Mean trabecular thickness | MTT | |
| Structure model index | SMI | |
| Trabecular area | Tb.Ar | |
| Trabecular number | Tb.N | |
| Trabecular separation | Tb.Sp | |
| Trabecular thickness | Tb.Th |
Range of parameter settings proven efficient in PEMF stimulation, divided according to different bone damage models studied.
| Magnetic Field (Range) | Frequency of the Trains of Pulses (Range) | Duration of Each | Overall Treatment | |
|---|---|---|---|---|
| Osteotomic damage | 0.2–2.8 mT | 10–75 Hz | 2 h–24 h | 2–21 weeks |
| Ovariectomy | 0.96–3.82 mT | 7.5–50 Hz | 40 m–8 h | 4–8 weeks |
| Glucocorticoid | 1.2–4 mT | 8–50 Hz | 40 m–4 h | 4–12 weeks |
| Diabetes induced | 2–3.8 mT | 8–15 Hz | 40 m–8 h | 8–12 weeks |
| Disuse osteopenia | 0.6–3.8 mT | 10–50 Hz | 40 m–8 h | 1–12 weeks |